Regular Low-Frequency HemoperfusionNCT07348913
Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients
An observational study of Regular Low-Frequency Hemoperfusion and Medium- to Long-Term Prognosis, run by Yunfeng Xia at 1 site in China.
Trial summary
Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients. Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Regular Low-Frequency Hemoperfusion, Medium- to Long-Term Prognosis, Maintenance Dialysis Patients
- How many people
- 879 participants
- Where
- 1 siteChina
- Study dates
- 1 Jan 2015to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who received MHD treatment at the Hemodialysis Center of the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 31, 2024. Included patients were aged ≥18 years, received dialysis three times a week (each session lasting 3-4 hours), had basically complete clinical and laboratory records, and were followed up at our center for at least 6 months.
Who may be able to join
- Included patients were aged ≥18 years
- Undergo dialysis treatment three times a week (each session lasting 3-4 hours)
- Having basically complete clinical and laboratory records, and having received at least 6 months of follow-up at this center
Who cannot join
- Under 18 years old
- Does not receive dialysis three times a week (each session lasts 3-4 hours)
- Does not have basic complete clinical and laboratory records, and has not been followed up at this center for at least 6 months
Trial locations and contacts
1 site in 1 country.
China1 site
First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400016
About this study
Official title: Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients: A Real-World Single-Center Retrospective Study
Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients.
Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Patients were divided into a hemoperfusion group (receiving regular low-frequency hemoperfusion once monthly) and a non-hemoperfusion group. Propensity score matching (PSM) was used to balance baseline characteristics. Differences in cumulative all-cause and cardiovascular/cerebrovascular mortality between the two groups before and after matching were compared. A competing risk model was employed to analyze mortality risk.
Read the detailed description
Clinical and laboratory data were collected for all enrolled patients. These included age, sex, underlying medical conditions, dialysis vintage, blood pressure, serum albumin, hemoglobin, platelet count, C-reactive protein (CRP), serum calcium, serum phosphorus, intact parathyroid hormone (iPTH), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and serum β2-microglobulin. Time-averaged mean values were calculated for blood pressure and laboratory parameters across the entire follow-up period. Data on cardiovascular/cerebrovascular death and all-cause mortality over the past ten years were also compiled.
Given the considerably larger size of the Hemoperfusion Group compared with the Non-Hemoperfusion Group, propensity score matching (PSM) was performed by specialized statisticians during data processing to balance baseline characteristics between the two groups. This approach enabled a systematic assessment of the effect of regular low-frequency hemoperfusion on cardiovascular/cerebrovascular and all-cause mortality in MHD patients.
- Conditions
- Regular Low-Frequency Hemoperfusion, Medium- to Long-Term Prognosis, Maintenance Dialysis Patients, Retrospective Study
- Keywords
- Hemoperfusion, Maintenance Dialysis, Propensity Score Matching, Survival Analysis, Competing Risk, Cardiovascular/Cerebrovascular Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| hemoperfusion group | receive regular low-frequency hemoperfusion once monthly | |
| non-hemoperfusion group | not receive regular low-frequency hemoperfusion once monthly |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cardiovascular/Cerebrovascular Death
Measured: 1, 3, 5, and 10 years
all-cause mortality
Measured: 1, 3, 5, and 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start1 Jan 2015
- Primary completion31 Dec 2024
- Study completion31 Dec 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Regular Low-Frequency HemoperfusionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 879 participants (actual)
Sponsor and investigators
- Lead sponsor
- Yunfeng Xia
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Yunfeng Xia, First Affiliated Hospital of Chongqing Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07348913
- Sponsor's protocol ID
- Chong qing Medical University
- Status last verified
- Jan 2025
- First submitted
- 29 Dec 2025
- Last updated
- 16 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Regular Low-Frequency Hemoperfusion on Medium- to Long-Term Prognosis in Maintenance Dialysis Patients: A Real-World Single-Center Retrospective Study
- ClinicalTrials.gov ID
- NCT07348913
- Acronym / sponsor ID
- Chong qing Medical University
- Conditions
- Regular Low-Frequency Hemoperfusion, Medium- to Long-Term Prognosis, Maintenance Dialysis Patients, Retrospective Study
- Keywords
- Hemoperfusion, Maintenance Dialysis, Propensity Score Matching, Survival Analysis, Competing Risk, Cardiovascular/Cerebrovascular Death
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 879 participants (actual)
- Lead sponsor
- Yunfeng XiaUniversity, hospital or other
- Study start
- 1 Jan 2015 (actual)
- Primary completion
- 31 Dec 2024 (actual)
- Study completion
- 31 Dec 2024 (actual)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Objective: To investigate the effect of regular low-frequency hemoperfusion on all-cause mortality and cardiovascular/cerebrovascular mortality risk in maintenance hemodialysis (MHD) patients.
Methods: Data from MHD patients over the past 10 years at our blood purification center were retrospectively collected. Patients were divided into a hemoperfusion group (receiving regular low-frequency hemoperfusion once monthly) and a non-hemoperfusion group. Propensity score matching (PSM) was used to balance baseline characteristics. Differences in cumulative all-cause and cardiovascular/cerebrovascular mortality between the two groups before and after matching were compared. A competing risk model was employed to analyze mortality risk.
Detailed description
Clinical and laboratory data were collected for all enrolled patients. These included age, sex, underlying medical conditions, dialysis vintage, blood pressure, serum albumin, hemoglobin, platelet count, C-reactive protein (CRP), serum calcium, serum phosphorus, intact parathyroid hormone (iPTH), total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), triglycerides, and serum β2-microglobulin. Time-averaged mean values were calculated for blood pressure and laboratory parameters across the entire follow-up period. Data on cardiovascular/cerebrovascular death and all-cause mortality over the past ten years were also compiled.
Given the considerably larger size of the Hemoperfusion Group compared with the Non-Hemoperfusion Group, propensity score matching (PSM) was performed by specialized statisticians during data processing to balance baseline characteristics between the two groups. This approach enabled a systematic assessment of the effect of regular low-frequency hemoperfusion on cardiovascular/cerebrovascular and all-cause mortality in MHD patients.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| hemoperfusion group | – | –receive regular low-frequency hemoperfusion once monthly |
| non-hemoperfusion group | – | –not receive regular low-frequency hemoperfusion once monthly |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who received MHD treatment at the Hemodialysis Center of the First Affiliated Hospital of Chongqing Medical University from January 2015 to December 31, 2024. Included patients were aged ≥18 years, received dialysis three times a week (each session lasting 3-4 hours), had basically complete clinical and laboratory records, and were followed up at our center for at least 6 months.
Key inclusion criteria (3 listed)
- Included patients were aged ≥18 years
- Undergo dialysis treatment three times a week (each session lasting 3-4 hours)
- Having basically complete clinical and laboratory records, and having received at least 6 months of follow-up at this center
Key exclusion criteria (3 listed)
- Under 18 years old
- Does not receive dialysis three times a week (each session lasts 3-4 hours)
- Does not have basic complete clinical and laboratory records, and has not been followed up at this center for at least 6 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Cardiovascular/Cerebrovascular Death
Time frame: 1, 3, 5, and 10 years
all-cause mortality
Time frame: 1, 3, 5, and 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jan 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Regular Low-Frequency Hemoperfusion and Medium- to Long-Term Prognosis, run by Yunfeng Xia at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cardiovascular/Cerebrovascular Death (time frame: 1, 3, 5, and 10 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jan 2026.